1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker
  4. >>User Fee Goal Dates

US FDA’s November Goal Dates Cannot Elevate 2024’s Novel Approvals To 2023 Levels

 
• By Bridget Silverman

Another record-breaking year for novel approvals looks out of reach, but the six novel agents with November goal dates show the continued strength of rare disease drug development.

The FDA's November calendar includes user fee goal dates for six novel agents. (Shutterstock)

With only six novel candidates on its November 2024 user fee calendar, the US Food and Drug Administration is running out of chances to reach its 2023 total of 72 new molecular entities and novel biologic approvals.

Through the end of October 2024, the FDA cleared 45 novel agents, including 38 from the Center for Drug Evaluation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fee Goal Dates

America Next: Most Novel Agents With July Goal Dates Have Been Approved Overseas

 
• By Bridget Silverman

The US FDA will not be in its usual position as the first regulator to approve novel drugs, with only one of the six novel candidates on the July user fee calendar seeking its first approval worldwide in the US

US FDA’s November Goal Dates Cannot Elevate 2024’s Novel Approvals To 2023 Levels

 
• By Bridget Silverman

Another record-breaking year for novel approvals looks out of reach, but the six novel agents with November goal dates show the continued strength of rare disease drug development.

More from United States

Senate Bill Would Boost Oversight Of US FDA User Fee Program Following Trump Reorganization

 
• By Sarah Karlin-Smith

Senate appropriators also put FDA on notice regarding recent meetings and compliance with the Federal Advisory Committees Act, signal positive news on rare pediatric diseases, and offer hints of other agency areas they have close eyes on.

‘Seize the Moment:’ European Drug Regulators Called To Act On Changes In US

 
• By Francesca Bruce

European regulators must work hard to maintain and build vital but fragile trust in science and processes, said speakers at an event celebrating the European Medicines Agency 30th anniversary.

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By Sue Sutter

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.